Description:
Metavas MR (Trimetazidine Dihydrochloride) is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Metavas MR (Trimetazidine) inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heat more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.
Indications
Pharmacology
Pregnancy & Lactation
Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Nursing Mothers: There is no information on the secretion of Trimetazidine into breast milk. However, breast feeding should be discontinued if the use of Trimetazidine is considered essential.
Reviews
There are no reviews yet.